Developer docs
API playgroundTry for free, no card

Search company profiles

Allelica

Full company profile

uuid0000igx

Namestring
Allelica
Legal namestring
Allelica, Inc.
Websiteurl
allelica.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
polygenic risk score software, clinical genomic testing, precision medicine analytics, multi-ancestry PRS platform, clinical genetics laboratory software
Industry3 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Software Publishers513210
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Testing Laboratories8734
Product category
Clinical Genomics Software & Polygenic Risk Score Testing
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model6 records
1Clinical Genetic Testing Services
TypeSubscription Recurring
Description

Direct clinical genetic testing services for patients ordered through healthcare providers. Tests include PRS for cardiovascular disease, breast cancer, prostate cancer, and comprehensive AbsoluteDx panels. Revenue generated through insurance reimbursement and patient self-pay with financial assistance programs available.

allelica.com
2Software as a Service (SaaS) - PREDICT Module
TypeSubscription Recurring
Description

Annual subscription software for clinical genetics laboratories and health systems to perform ancestry-informed PRS analysis and clinical-grade reporting. Available on cloud or on-premises deployment.

allelica.com
3Software as a Service (SaaS) - DISCOVER & VALIDATE Modules
TypeSubscription Recurring
Description

SaaS platform for researchers to construct and validate new PRS. DISCOVER enables PRS development while VALIDATE tests predictive performance on independent datasets. Subscription-based cloud computing solution.

allelica.com
4Allelica Precision Server (Hardware/Software)
TypeOne Time License
Description

On-premises hardware and containerized software solution for CLIA-compliant genomic analysis. Sold to clinical laboratories requiring in-house data processing capabilities.

allelica.com
5Corporate Wellness - cardioriskSCORE
TypeSubscription Recurring
Description

Employee cardiovascular disease prevention program sold to employers. Includes DNA testing, risk assessment, and ongoing tracking through health assistant app. Generates savings on employee health insurance costs for employers.

allelica.com
6Clinical Trial Services
TypeProfessional Services
Description

PRS trial stratification services for pharmaceutical and biotech companies. Helps shorten trial timelines, reduce participant numbers, and identify subpopulations who benefit most from therapies.

morningstar.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations, Supply Chain
Pricing details3 tiers
1Insurance reimbursement for eligible patients
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Patients meeting medical necessity criteria (borderline or intermediate 10-year ASCVD risk, or family history of CAD) may be eligible for insurance reimbursement. Reimbursement varies on case-by-case basis. Financial assistance program available for patients with limited financial resources.

allelica.com
2Software subscription for clinical labs
ModelSubscriptionBilling cadenceAnnual
Notes

Annual subscription for PREDICT software module for clinical genetics laboratories and health systems. Available as cloud-based or on-premises deployment.

allelica.com
3Corporate wellness program pricing
ModelSubscriptionBilling cadenceAnnual
Notes

CardioriskSCORE program saves employers with more than 7,000 employees $1.4 million per year on average. Program cost not publicly disclosed.

allelica.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1AbsoluteDx™
Description

Brand name for Allelica's diagnostic products including breast cancer risk assessment tools.

allelica.com
+6 more records
Core offering1 text field

Allelica develops and sells multi-ancestry polygenic risk score (PRS) software and clinical genomic testing services that quantify inherited risk for common diseases such as cardiovascular disease, breast cancer, prostate cancer, and diabetes. Its portfolio includes cloud and on-premises software modules (PREDICT, DISCOVER, VALIDATE, Allelica Precision Server), clinical tests (PRS testing, AbsoluteDx, Breast Risk Reveal), and a corporate wellness program (cardioriskSCORE). The platform integrates genome-wide genetic variants with clinical risk factors and EHR workflows for healthcare providers, clinical laboratories, employers, and pharma/biotech customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 17% of high-risk employees identified that other assessments overlook
+7 more records
Product overview1 text field

Allelica is a precision medicine company offering a comprehensive genomic risk assessment platform. The core portfolio centers on polygenic risk score (PRS) testing — a platform of clinical tests and software modules designed to integrate genetics into clinical practice. The clinical tests include standalone PRS testing for multiple diseases (cardiovascular, cancer, diabetes), AbsoluteDx (a combined monogenic+polygenic solution), and Breast Risk Reveal (breast cancer-specific integrated assessment). The software suite comprises three SaaS modules: PREDICT for clinical genetics laboratories to generate PRS reports, DISCOVER for researchers to build new PRS, and VALIDATE for testing PRS on independent datasets. Allelica Precision Server provides on-premises CLIA-compliant deployment. The company also offers cardioriskSCORE as a workplace wellness solution. All products emphasize multi-ancestry calibration and integration with clinical workflows including EHR systems.

Product and service8 records
1PRS (Polygenic Risk Score) Clinical Testing
CategoryClinical Genetic Testing
Description

Clinical PRS testing service that aggregates the effects of thousands to millions of genetic variants to assess individual predisposition to common diseases including cardiovascular disease, diabetes, and various cancers. Tests are validated and calibrated for people of diverse ancestry using ancestry-specific thresholds and are ordered through healthcare providers.

2AbsoluteDx
CategoryClinical Genetic Testing
Description

Comprehensive monogenic plus polygenic clinical risk test that identifies carriers of pathogenic mutations and modulates penetrance through multi-ancestry polygenic risk scores. Combines low-coverage WGS (~3.2x coverage) with high-depth whole-exome sequencing (~96x coverage) to deliver risk assessment for breast cancer, prostate cancer, familial hypercholesterolemia, and comprehensive panels.

3Breast Risk Reveal
CategoryClinical Genetic Testing
Description

Integrated breast cancer risk assessment combining monogenic, polygenic, and clinical data using Tyrer-Cuzick and BOADICEA v7 models to deliver comprehensive individualized breast cancer risk estimates across all ancestries.

4PREDICT Module
CategoryGenomics Software (SaaS)
Description

Clinical genetics software module that integrates polygenic risk scores with clinical risk factors to provide detailed assessment of individual risk for common complex diseases. Generates PRS reports with ancestry-specific analysis, 10-year and lifetime risk of disease. Available as cloud or on-premises deployment for genetics laboratories with API integration to EHRs.

5DISCOVER Module
CategoryGenomics Software (SaaS)
Description

Cloud-based PRS development module enabling researchers to construct and validate new polygenic risk scores. Runs ten PRS development algorithms in parallel (including LDPred2, SCT, PRScs, SBayesR, lassosum, SVM, and Clumping & Thresholding) to identify the best predictive model for a given disease, producing publication-ready scores with standardized metrics.

6VALIDATE Module
CategoryGenomics Software (SaaS)
Description

PRS validation module enabling researchers to test the transferability and predictive power of polygenic risk scores on independent datasets. Assesses applicability of PRS to populations of diverse ancestry, addressing the lack of diversity in most published PRS research.

7Allelica Precision Server (APS)
CategoryGenomics Software & On-Premises Appliance
Description

CLIA-compliant on-premises server solution for polygenic risk score, pharmacogenomics, and carrier screening analysis. Available as both hardware and containerized software. Designed for medical laboratories requiring in-lab data processing with regulatory compliance (CLIA, HIPAA) and enhanced data security without external data transfers.

8cardioriskSCORE
CategoryCorporate Wellness Program
Description

Corporate cardiovascular disease prevention program utilizing genomics and real-world data to prevent heart disease. Combines polygenic DNA testing with traditional risk factors to identify high-risk employees, deliver personalized prevention recommendations, and generate health insurance cost savings. Includes a Health Assistant App for tracking blood pressure, cholesterol, and smoking status.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Allelica selected as PRS testing collaborator for PROACT 3 clinical trial at Mass General Brigham. The randomized trial evaluates 500 adults using Allelica's multi-ancestry CAD PRS to measure how disclosure of genetic risk influences LDL cholesterol and cardiovascular health behaviors over 12 months. Trial led by Dr. Akl Fahed and follows NIH-funded PROACT 1 and 2 trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Partnership with VA to conduct clinical trial evaluating whether genomics-informed personalized care can lower cardiovascular event risk among veterans not currently on cholesterol-lowering medication. Trial uses Allelica's CAD PRS and pharmacogenetics testing to assess statin tolerance and personalized lipid-lowering strategies.

3Cambridge Enterprise (University of Cambridge)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-22
Description

Commercial license agreement with Cambridge Enterprise to incorporate BOADICEA v7 breast cancer risk prediction model into Allelica's clinical risk assessment platform. The model integrates genetic variants, polygenic risk scores, family history, and clinical risk factors to generate quantitative breast cancer risk estimates.

biospace.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

UAB Cardiogenomics Clinic and Allelica partnership for clinical implementation study of coronary artery disease PRS. Study evaluates clinical value of PRS in real-world healthcare settings.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-09
Description

Partnership with Broad Institute for AbsoluteDx launch - comprehensive genetic test combining monogenic and polygenic risk assessments. Broad Institute collaboration provides validation and scientific credibility for the integrated testing approach.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-31
Description

Integration of Allelica's bioinformatics software with Thermo Fisher Scientific's Axiom Human Genotyping Microarrays. Allows researchers to create and implement PRS for disease risk prediction. Integrated solution advances precision medicine by enabling more accessible genomic research workflows.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Partnership for breast cancer PRS study with Taiwanese biobanks. SP BioMed and Allelica collaborate on PRS analysis using Taiwanese population data.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Allelica provides multi-ancestry PRS technology to Baylor College of Medicine for clinical implementation. Collaboration advances precision medicine by integrating PRS into patient care, improving risk assessment across diverse populations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

University of Sydney secured AU$1.4M grant plus AU$2M from industry and partnered with Allelica to advance heart disease prevention strategies through PRS application. Collaboration focused on cardiac polygenic risk scores research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Collaboration with Invitae to build ancestry-informed polygenic risk score for breast cancer. Combines Invitae's genetic testing capabilities with Allelica's multi-ancestry PRS technology.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Collaboration with Labcorp to ensure polygenic and monogenic risk factors are assessed and accounted for in the patient journey through multi-ancestry PRS analysis.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Yale researcher selected Allelica to expand PRS research on childhood neuropsychiatric disorders. Collaboration focused on developing PRS for psychiatric conditions using Allelica's DISCOVER platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based genomics company building polygenic risk scores for common disease prediction and pharmaceutical trial stratification. Directly comparable to Allelica in PRS technology, customer base (pharma + health systems), and multi-ancestry focus.

TypeDirect peer
Description

Clinical genomics AI platform offering variant interpretation and reporting software to hospitals and labs globally. Comparable SaaS-based clinical genomics workflow, multi-modality analysis, and health system distribution model.

TypeDirect peer
Description

Genomics data and analytics platform providing PRS pipelines, genomic data management, and pharma research services. Overlaps with Allelica's DISCOVER/VALIDATE modules and pharma trial stratification offering.

4Genomic Prediction
TypeDirect peer
Description

Clinical PRS laboratory offering polygenic risk testing for multiple diseases. Directly comparable to Allelica in clinical PRS testing service and multi-ancestry validation focus.

TypeDirect peer
Description

Clinical genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomics tests to health systems and employers. Comparable clinical genetic testing menu, employer wellness programs, and EHR-integrated ordering workflow.

TypeBroad incumbent
Description

Established genetic testing company with broad hereditary cancer, pharmacogenomic, and prenatal testing menus. Overlaps with Allelica in breast cancer risk assessment (including BOADICEA/Tyrer-Cuzick integration) but operates as a much larger incumbent with established payer relationships.

TypeBroad incumbent
Description

Consumer genetic testing company with growing health and PRS offerings. Comparable ancestry-aware genetic reports and DTC distribution, but operates at significantly larger scale and is also a therapeutic developer.

8Tempus AI
TypeBroad incumbent
Description

Precision medicine data and AI platform spanning oncology, cardiology, and pharma services. Comparable in health system enterprise sales, clinical-genomic data integration, and pharma trial enablement.

TypeBroad incumbent
Description

Sequencing platform leader that has also licensed Allelica's PRS software. Comparable in genomics workflow tools for clinical and research labs, but operates as a much larger incumbent with broader portfolio beyond PRS.

TypeOthers
Description

National diagnostic laboratory partner collaborating with Allelica to incorporate multi-ancestry PRS into patient testing workflows. Serves as both a partnership channel and indirect benchmark for clinical lab scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Allelica

Clinical Genomics Software & Polygenic Risk Score Testingallelica.com

Allelica firmographics

Firmographics
Name
Allelica
Legal name
Allelica, Inc.
Website
https://allelica.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Allelica industry classification

Industry
Product category
Clinical Genomics Software & Polygenic Risk Score Testing
NAICS
Medical and Diagnostic Laboratories (6215), Software Publishers (513210)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Polygenic risk score software
  • Clinical genomic testing
  • Precision medicine analytics
  • Multi-ancestry PRS platform
  • Clinical genetics laboratory software

Where Allelica is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Allelica business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Clinical Genetic Testing Services: Direct clinical genetic testing services for patients ordered through healthcare providers. Tests include PRS for cardiovascular disease, breast cancer, prostate cancer, and comprehensive AbsoluteDx panels. Revenue generated through insurance reimbursement and patient self-pay with financial assistance programs available.
  2. Software as a Service (SaaS) - PREDICT Module: Annual subscription software for clinical genetics laboratories and health systems to perform ancestry-informed PRS analysis and clinical-grade reporting. Available on cloud or on-premises deployment.
  3. Software as a Service (SaaS) - DISCOVER & VALIDATE Modules: SaaS platform for researchers to construct and validate new PRS. DISCOVER enables PRS development while VALIDATE tests predictive performance on independent datasets. Subscription-based cloud computing solution.
  4. Allelica Precision Server (Hardware/Software): On-premises hardware and containerized software solution for CLIA-compliant genomic analysis. Sold to clinical laboratories requiring in-house data processing capabilities.
  5. Corporate Wellness - cardioriskSCORE: Employee cardiovascular disease prevention program sold to employers. Includes DNA testing, risk assessment, and ongoing tracking through health assistant app. Generates savings on employee health insurance costs for employers.
  6. Clinical Trial Services: PRS trial stratification services for pharmaceutical and biotech companies. Helps shorten trial timelines, reduce participant numbers, and identify subpopulations who benefit most from therapies.

Pricing tiers

ModelBillingPrice
SubscriptionPay-as-you-goInsurance reimbursement for eligible patients
SubscriptionAnnualSoftware subscription for clinical labs
SubscriptionAnnualCorporate wellness program pricing

Go-to-market motion4 records

Distribution channels6 records

Marketing channels8 records

Allelica product offering

Product offering

Core offering

Allelica develops and sells multi-ancestry polygenic risk score (PRS) software and clinical genomic testing services that quantify inherited risk for common diseases such as cardiovascular disease, breast cancer, prostate cancer, and diabetes. Its portfolio includes cloud and on-premises software modules (PREDICT, DISCOVER, VALIDATE, Allelica Precision Server), clinical tests (PRS testing, AbsoluteDx, Breast Risk Reveal), and a corporate wellness program (cardioriskSCORE). The platform integrates genome-wide genetic variants with clinical risk factors and EHR workflows for healthcare providers, clinical laboratories, employers, and pharma/biotech customers.

Product overview

Allelica is a precision medicine company offering a comprehensive genomic risk assessment platform. The core portfolio centers on polygenic risk score (PRS) testing — a platform of clinical tests and software modules designed to integrate genetics into clinical practice. The clinical tests include standalone PRS testing for multiple diseases (cardiovascular, cancer, diabetes), AbsoluteDx (a combined monogenic+polygenic solution), and Breast Risk Reveal (breast cancer-specific integrated assessment). The software suite comprises three SaaS modules: PREDICT for clinical genetics laboratories to generate PRS reports, DISCOVER for researchers to build new PRS, and VALIDATE for testing PRS on independent datasets. Allelica Precision Server provides on-premises CLIA-compliant deployment. The company also offers cardioriskSCORE as a workplace wellness solution. All products emphasize multi-ancestry calibration and integration with clinical workflows including EHR systems.

Differentiator

Problem solved

Functional benefit

Brands

  • AbsoluteDx™: Brand name for Allelica's diagnostic products including breast cancer risk assessment tools.
  • Breast Risk Reveal™
  • CardioriskSCORE
  • Allelica Precision Server (APS)
  • PREDICT
  • DISCOVER
  • VALIDATE

Products and services

  • PRS (Polygenic Risk Score) Clinical Testing Clinical PRS testing service that aggregates the effects of thousands to millions of genetic variants to assess individual predisposition to common diseases including cardiovascular disease, diabetes, and various cancers. Tests are validated and calibrated for people of diverse ancestry using ancestry-specific thresholds and are ordered through healthcare providers.
  • AbsoluteDx Comprehensive monogenic plus polygenic clinical risk test that identifies carriers of pathogenic mutations and modulates penetrance through multi-ancestry polygenic risk scores. Combines low-coverage WGS (~3.2x coverage) with high-depth whole-exome sequencing (~96x coverage) to deliver risk assessment for breast cancer, prostate cancer, familial hypercholesterolemia, and comprehensive panels.
  • Breast Risk Reveal Integrated breast cancer risk assessment combining monogenic, polygenic, and clinical data using Tyrer-Cuzick and BOADICEA v7 models to deliver comprehensive individualized breast cancer risk estimates across all ancestries.
  • PREDICT Module Clinical genetics software module that integrates polygenic risk scores with clinical risk factors to provide detailed assessment of individual risk for common complex diseases. Generates PRS reports with ancestry-specific analysis, 10-year and lifetime risk of disease. Available as cloud or on-premises deployment for genetics laboratories with API integration to EHRs.
  • DISCOVER Module Cloud-based PRS development module enabling researchers to construct and validate new polygenic risk scores. Runs ten PRS development algorithms in parallel (including LDPred2, SCT, PRScs, SBayesR, lassosum, SVM, and Clumping & Thresholding) to identify the best predictive model for a given disease, producing publication-ready scores with standardized metrics.
  • VALIDATE Module PRS validation module enabling researchers to test the transferability and predictive power of polygenic risk scores on independent datasets. Assesses applicability of PRS to populations of diverse ancestry, addressing the lack of diversity in most published PRS research.
  • Allelica Precision Server (APS) CLIA-compliant on-premises server solution for polygenic risk score, pharmacogenomics, and carrier screening analysis. Available as both hardware and containerized software. Designed for medical laboratories requiring in-lab data processing with regulatory compliance (CLIA, HIPAA) and enhanced data security without external data transfers.
  • cardioriskSCORE Corporate cardiovascular disease prevention program utilizing genomics and real-world data to prevent heart disease. Combines polygenic DNA testing with traditional risk factors to identify high-risk employees, deliver personalized prevention recommendations, and generate health insurance cost savings. Includes a Health Assistant App for tracking blood pressure, cholesterol, and smoking status.

Quantifiable outcome

  • 17% of high-risk employees identified that other assessments overlook
  • +7 more outcomes

Companies that use Allelica

Customer profile

Named customers14 records

Segments5 records

Ideal customer profiles5 records

Allelica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature8 records

Allelica partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • Mass General BrighamcoreStrategic or Co-development Partner · 7 April 2026Allelica selected as PRS testing collaborator for PROACT 3 clinical trial at Mass General Brigham. The randomized trial evaluates 500 adults using Allelica's multi-ancestry CAD PRS to measure how disclosure of genetic risk influences LDL cholesterol and cardiovascular health behaviors over 12 months. Trial led by Dr. Akl Fahed and follows NIH-funded PROACT 1 and 2 trials.
  • US Department of Veterans AffairscoreStrategic or Co-development Partner · 17 March 2026Partnership with VA to conduct clinical trial evaluating whether genomics-informed personalized care can lower cardiovascular event risk among veterans not currently on cholesterol-lowering medication. Trial uses Allelica's CAD PRS and pharmacogenetics testing to assess statin tolerance and personalized lipid-lowering strategies.
  • Cambridge Enterprise (University of Cambridge)coreOEM/ Whitelabel/ Licensing Partner · 22 January 2026Commercial license agreement with Cambridge Enterprise to incorporate BOADICEA v7 breast cancer risk prediction model into Allelica's clinical risk assessment platform. The model integrates genetic variants, polygenic risk scores, family history, and clinical risk factors to generate quantitative breast cancer risk estimates.
  • UAB Cardiogenomics ClinicminorStrategic or Co-development Partner · 1 January 2026UAB Cardiogenomics Clinic and Allelica partnership for clinical implementation study of coronary artery disease PRS. Study evaluates clinical value of PRS in real-world healthcare settings.
  • Broad InstitutecoreStrategic or Co-development Partner · 9 October 2025Partnership with Broad Institute for AbsoluteDx launch - comprehensive genetic test combining monogenic and polygenic risk assessments. Broad Institute collaboration provides validation and scientific credibility for the integrated testing approach.
  • Thermo Fisher ScientificcoreTechnology or Integration · 31 July 2024Integration of Allelica's bioinformatics software with Thermo Fisher Scientific's Axiom Human Genotyping Microarrays. Allows researchers to create and implement PRS for disease risk prediction. Integrated solution advances precision medicine by enabling more accessible genomic research workflows.
  • SP BioMedminorStrategic or Co-development Partner · 1 January 2023Partnership for breast cancer PRS study with Taiwanese biobanks. SP BioMed and Allelica collaborate on PRS analysis using Taiwanese population data.
  • Baylor College of MedicinecoreStrategic or Co-development Partner · 1 January 2022Allelica provides multi-ancestry PRS technology to Baylor College of Medicine for clinical implementation. Collaboration advances precision medicine by integrating PRS into patient care, improving risk assessment across diverse populations.
  • University of SydneycoreStrategic or Co-development Partner · 1 January 2022University of Sydney secured AU$1.4M grant plus AU$2M from industry and partnered with Allelica to advance heart disease prevention strategies through PRS application. Collaboration focused on cardiac polygenic risk scores research.
  • InvitaecoreStrategic or Co-development Partner · 1 January 2022Collaboration with Invitae to build ancestry-informed polygenic risk score for breast cancer. Combines Invitae's genetic testing capabilities with Allelica's multi-ancestry PRS technology.
  • LabcorpminorStrategic or Co-development Partner · 1 January 2022Collaboration with Labcorp to ensure polygenic and monogenic risk factors are assessed and accounted for in the patient journey through multi-ancestry PRS analysis.
  • Yale School of MedicineminorStrategic or Co-development Partner · 1 January 2022Yale researcher selected Allelica to expand PRS research on childhood neuropsychiatric disorders. Collaboration focused on developing PRS for psychiatric conditions using Allelica's DISCOVER platform.

Scale indicators10 records

Recent moves6 records

Expansion highlights3 records

Allelica competitors and assessment

Company assessment

Direct peers

  • Genomics plc: UK-based genomics company building polygenic risk scores for common disease prediction and pharmaceutical trial stratification. Directly comparable to Allelica in PRS technology, customer base (pharma + health systems), and multi-ancestry focus.
  • SOPHiA Genetics: Clinical genomics AI platform offering variant interpretation and reporting software to hospitals and labs globally. Comparable SaaS-based clinical genomics workflow, multi-modality analysis, and health system distribution model.
  • BC Platforms: Genomics data and analytics platform providing PRS pipelines, genomic data management, and pharma research services. Overlaps with Allelica's DISCOVER/VALIDATE modules and pharma trial stratification offering.
  • Genomic Prediction: Clinical PRS laboratory offering polygenic risk testing for multiple diseases. Directly comparable to Allelica in clinical PRS testing service and multi-ancestry validation focus.
  • Color Health: Clinical genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomics tests to health systems and employers. Comparable clinical genetic testing menu, employer wellness programs, and EHR-integrated ordering workflow.

Broad incumbents

  • Myriad Genetics: Established genetic testing company with broad hereditary cancer, pharmacogenomic, and prenatal testing menus. Overlaps with Allelica in breast cancer risk assessment (including BOADICEA/Tyrer-Cuzick integration) but operates as a much larger incumbent with established payer relationships.
  • 23andMe: Consumer genetic testing company with growing health and PRS offerings. Comparable ancestry-aware genetic reports and DTC distribution, but operates at significantly larger scale and is also a therapeutic developer.
  • Tempus AI: Precision medicine data and AI platform spanning oncology, cardiology, and pharma services. Comparable in health system enterprise sales, clinical-genomic data integration, and pharma trial enablement.
  • Illumina: Sequencing platform leader that has also licensed Allelica's PRS software. Comparable in genomics workflow tools for clinical and research labs, but operates as a much larger incumbent with broader portfolio beyond PRS.

Others

  • Labcorp: National diagnostic laboratory partner collaborating with Allelica to incorporate multi-ancestry PRS into patient testing workflows. Serves as both a partnership channel and indirect benchmark for clinical lab scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Allelica social profiles

Digital presence

Allelica compliance and trust

Trust signal

Compliance7 records

Allelica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Allelica leadership team

Management profile

Number of profiles

Profiles4 records

Allelica funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Allelica M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allelica

What does Allelica do?

Allelica develops and sells multi-ancestry polygenic risk score (PRS) software and clinical genomic testing services that quantify inherited risk for common diseases such as cardiovascular disease, breast cancer, prostate cancer, and diabetes. Its portfolio includes cloud and on-premises software modules (PREDICT, DISCOVER, VALIDATE, Allelica Precision Server), clinical tests (PRS testing, AbsoluteDx, Breast Risk Reveal), and a corporate wellness program (cardioriskSCORE). The platform integrates genome-wide genetic variants with clinical risk factors and EHR workflows for healthcare providers, clinical laboratories, employers, and pharma/biotech customers.

Is Allelica a public or private company?

Allelica is a private company. It is classified as venture growth investor backed and is currently operating.

When was Allelica founded?

Allelica was founded in 2018. It employs 11 to 50 people.

Where is Allelica based?

Allelica is headquartered in San Francisco, United States, in the North America region.

How does Allelica make money?

Six revenue lines are on record. Clinical Genetic Testing Services are the primary driver. The others are software as a Service (SaaS) - PREDICT Module, software as a Service (SaaS) - DISCOVER & VALIDATE Modules, allelica Precision Server (Hardware/Software), corporate Wellness - cardioriskSCORE and clinical Trial Services.

Who are Allelica's main competitors?

Direct peers on record are Genomics plc, SOPHiA Genetics, BC Platforms, Genomic Prediction and Color Health. Broad incumbents are Myriad Genetics, 23andMe, Tempus AI and Illumina. Labcorp is listed as an others.

Does Allelica have an API?

No public API is recorded for Allelica.

What industry is Allelica in?

Allelica's product category is Clinical Genomics Software & Polygenic Risk Score Testing. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAANAL, Population Genomics & Preventive Precision Health Programs. Its NAICS code is 6215 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magCleerly, Allelica Partner on Risk Score Test for Coronary Artery DiseaseCleerly and Allelica have partnered to launch the Cleerly Polygenic Cardiovascular Risk Score Test, a laboratory-developed assay that analyzes genetic variants from saliva samples to estimate inherited risk of coronary artery disease. The test, validated across diverse populations, can identify up to one in four individuals as high genetic risk and is designed to complement Cleerly's FDA-cleared AI-enabled coronary CT imaging platform. The test is now available to U.S. physicians, enabling physicians to combine genetic risk assessment with advanced plaque imaging for more personalized cardiovascular care.Business Wire BlogCleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery DiseaseCleerly and Allelica announced a partnership to launch the Cleerly Polygenic Cardiovascular Risk Score Test, which uses Allelica's multi-ancestry PRS technology to identify individuals with an inherited predisposition to coronary artery disease. The test, performed using a saliva sample in a CLIA-certified laboratory, can be used independently or alongside Cleerly's FDA-cleared AI-enabled coronary CT imaging analysis. The test is now available to physicians in the US, with validation studies showing that up to one in four individuals may be flagged as high genetic risk.AijournAllelica powers PROACT 3 clinical trial with multi-ancestry polygenic risk score testingAllelica has been selected as the PRS testing collaborator for the PROACT 3 clinical trial at Mass General Brigham, led by Dr. Akl Fahed. The randomized trial will evaluate 500 adults using Allelica's multi-ancestry coronary artery disease polygenic risk score to measure how disclosure of genetic risk influences LDL cholesterol levels and cardiovascular health behaviors over 12 months. PROACT 3 follows the ongoing NIH-funded PROACT 1 and 2 trials and addresses whether receiving a genetic risk score improves key cardiovascular measures in a real-world health system setting.PR NewswireAllelica powers PROACT 3 clinical trial with multi-ancestry polygenic risk score testingAllelica, a precision medicine company, is participating in the PROACT 3 clinical trial at Massachusetts General Brigham to test the impact of polygenic risk score disclosure on cardiovascular health. The trial, involving 500 adults, evaluates changes in LDL cholesterol and health behaviors after genetic risk disclosure.MorningstarAllelica powers PROACT 3 clinical trial with multi-ancestry polygenic risk score testingAllelica has been selected as the polygenic risk score (PRS) testing collaborator for the PROACT 3 clinical trial at Mass General Brigham, a randomized trial of 500 adults evaluating whether disclosure of coronary artery disease genetic risk scores influences LDL cholesterol levels and cardiovascular health behaviors. The trial, led by principal investigator Dr. Akl Fahed, follows the NIH-funded PROACT 1 and 2 trials and uses Allelica's multi-ancestry CAD PRS, which was published in Nature Communications in 2023. Allelica CEO Dr. Giordano Botta stated the trial aligns with the company's mission to provide diagnostics that improve patient care.PR NewswireVA and Allelica partner on clinical study to assess the impact of polygenic risk score and pharmacogenomics testing in cardiovascular disease preventionThe U.S. Department of Veterans Affairs has partnered with Allelica to conduct a clinical genomics study aimed at reducing cardiovascular risk in veterans. The randomized trial will enroll at-risk veterans not currently on cholesterol-lowering medications, providing either standard care or a genomic risk assessment using polygenic risk scores for coronary artery disease and SLCO1B1 pharmacogenetics testing for statin tolerance. Findings from this study have the potential to inform how lipid-lowering drugs are prescribed across the VA healthcare system and beyond, benefiting millions of individuals at risk for cardiovascular disease.GenomeWebVA, Allelica Partner on Clinical Cardiovascular Disease Prevention StudyAllelica has partnered with the US Department of Veterans Affairs to conduct a clinical trial evaluating whether genomics-informed personalized care can lower cardiovascular event risk among veterans not currently on cholesterol-lowering medication. The trial will use Allelica's coronary artery disease polygenic risk score and pharmacogenetics testing to assess statin tolerance and whether personalized lipid-lowering strategies improve adherence and outcomes. The partnership aligns with recent recognition by the American College of Cardiology and American Heart Association, who included Allelica's CAD-PRS as a risk-enhancing factor in their 2026 cardiovascular risk assessment guidelines.National TodayPolygenic Risk Score Recognized in 2026 ACC/AHA GuidelinesAllelica announced that polygenic risk scores have been recognized as a risk-enhancing factor in the 2026 American College of Cardiology and American Heart Association Guidelines for cardiovascular risk assessment, with the guidelines specifically citing Allelica's study on a multi-ancestry polygenic risk score for coronary artery disease. The recognition marks a significant milestone in cardiovascular prevention, providing clinicians with an additional tool to identify individuals at genetic risk before symptoms or clinical disease appear. Allelica is now working with payers to broaden insurance coverage and has implemented a financial assistance program to expand patient access to genetic testing.PR NewswirePolygenic Risk Score Recognized in the 2026 ACC/AHA Guidelines, Allelica Multi-Ancestry CAD Polygenic Risk Score Study CitedAllelica announced that polygenic risk scores have been recognized as a risk-enhancing factor in the 2026 ACC/AHA Guidelines for cardiovascular risk assessment, with the guidelines specifically citing Allelica's multi-ancestry polygenic risk score study for coronary artery disease. The recognition marks a shift toward earlier detection of inherited cardiovascular risk, potentially enabling prevention before symptoms or clinical disease appear. Allelica is now working to expand insurance coverage and has implemented a financial assistance program to increase patient access to genetic risk testing.